EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Gentium S.p.A. (Nasdaq: GENT) today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program for the European Group for Blood and Marrow Transplantation's (EBMT) 36th Annual Meeting, to be held in Vienna, March 21-24, 2010. The abstract will be presented by Selim Corbacioglu, MD, University of Regensburg (Germany), at the opening session of the annual meeting (Hall A) on Sunday, March 21, 2010 at 7:20 PM local time.  

Defibrotide will also be featured in a satellite symposium entitled, "Defibrotide for the prevention and treatment of hepatic veno-occlusive disease following stem cell transplantation," on Sunday March 21 from 9:00 AM – 10:30 AM local time in the Austria Center, Hall G/H.  A separate abstract, "Defibrotide protects human microvascular endothelial cells from fludarabine-mediated pro-inflammatory and pro-apoptotic signals: a microarray (Affimetrix) analysis," will also be presented on Tuesday, March 23 from 5:30 PM until 7:00 PM at the poster session (P 908).